Download Sample Brochure @ http://tinyurl.com/hgprt3e “Candidiasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. Read Analysis @ http://www.marketintelreports.com/report/DIIR2016041/candidiasisglobal-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2016

1. Candidiasis-Global API Manufacturers, Marketed
and Phase III Drugs Landscape, 2016
“Candidiasis-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2016”, provides comprehensive insights about the marketed drugs,
drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.
Published on - 01 January, 2016 | Number of pages : 100
Single User Price: $2000

2. A key objective of the Candidiasis Report is to understand the market and pipeline
status of the drugs around the Candidiasis to explore the generic development
opportunities, licensing opportunities and to gain competitive advantage on
designing pipeline strategies. The Candidiasis Report provides the historical and
forecasted sales of the drugs till 2018.
The Report gives insights into patents providing the patent protection data and
marketing exclusivity of all the drugs across the Candidiasis. While the leading
brands, companies and chemicals are considered thoroughly, the report also
provides details on the Global API Manufacturers across the globe covering Drug
Master Filings of US, Europe and API Manufacturers in Asia specifically China and
India.
Click Here To Check Complete Report

3. Scope of Report:
 A snapshot of the global Market and Phase III therapeutics scenario for
Candidiasis.
 A review of the marketed products under prescription for Candidiasis,
regulatory information and marketing status.
 Coverage of global patent coverage and detailed commentaries on the US
patent challenges.
 Graphical representation of investigational products for patent expiry and
market exclusivities across the globe.
 Product profiles for marketed products for Candidiasis with complete
description of mechanism of action, therapeutic class, target, route(s) of
administration and chemical details.

4.  Coverage of API Manufacturers for Candidiasis drugs in the United States,
Europe and Asian Regions with location details.
 Coverage of Regulatory filings in the US, Europe, and Asia specifically
India and China for Candidiasis drugs.
 Coverage of Route of Synthesis of Active Pharmaceutical Ingredient
associated with Candidiasis drugs.
 Coverage of Candidiasis Phase III pipeline products featuring sections on
product description, mechanism of action, Chemical details and research
& development progress.
 Coverage of the United States Drug Master File (US DMF) available for
Phase III Pipeline Drugs.
 Key discontinued Marketed products.
 Global Sales Figure to 2018.
Download
Sample Brochure

5. Reasons to buy:
 Evaluate the marketing status and exclusivity details of Candidiasis key
products to exploit opportunities for generic drug development
opportunities.
 Identify and understand important and diverse types of therapeutics
under Phase III development for Candidiasis.
 Design effective counter-strategies to gain competitive advantage by
identifying the key patent expiry details and exclusivity with respect to
Candidiasis.
 API intelligence over marketed drugs for Candidiasis and gaining primary
intelligence over active ingredients manufacturers across the globe.
 API intelligence over leading Phase III Pipeline drugs.

6.  Develop and design strategies by identifying the API manufacturers for
Phase III Pipeline products to enhance and expand business potential and
scope.
 Understanding the scope of the Phase III Drugs with nil regulatory filings.
 Understanding the chemical route of synthesis of approved drugs for
Candidiasis.
 Uncovering opportunities in the rapidly growing US market.
Make an Inquiry
Before Buying

7. Candidiasis-Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2016
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of Candidiasis-Global API Manufacturers, Marketed and Phase III Drugs
Landscape, 2016 and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of Candidiasis Market
Report